We are live on
!
Find out more
EAM
Eventide Asset Management Portfolio holdings
AUM
$7.48B
1-Year Est. Return
104.76%
This Fund
S&P 500
This Quarter
Est. Return
+5.12%
1 Year Est. Return
+104.76%
3 Year Est. Return
+313.12%
5 Year Est. Return
+388.67%
10 Year Est. Return
+3,437.54%
AUM
$6.05B
AUM Growth
-$355M
(-5.5%)
Cap. Flow
-$238M
Cap. Flow
% of AUM
-3.93%
Top 10 Holdings %
Top 10 Hldgs %
22.18%
Holding
314
New
46
Increased
155
Reduced
70
Closed
36
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
GeneDx Holdings
WGS
|
+$41.9M |
| 2 |
Generac Holdings
GNRC
|
+$40.9M |
| 3 |
Vaxcyte
PCVX
|
+$24.8M |
| 4 |
Teradyne
TER
|
+$24.8M |
| 5 |
UL Solutions
ULS
|
+$21.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Mirum Pharmaceuticals
MIRM
|
+$64.4M |
| 2 |
GE Vernova
GEV
|
+$42.1M |
| 3 |
Inspire Medical Systems
INSP
|
+$40.6M |
| 4 |
RNAM
Avidity Biosciences
RNAM
|
+$37.8M |
| 5 |
Lithia Motors
LAD
|
+$33.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 39.12% |
| 2 | Industrials | 19.41% |
| 3 | Technology | 15.63% |
| 4 | Energy | 7.14% |
| 5 | Consumer Discretionary | 5.86% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
301
Rambus
RMBS
$9.88B
| – | – |
-10,330
| Closed | -$949K |
|
|
RNAM
302
DELISTED
Avidity Biosciences
RNAM
| – | – |
-524,643
| Closed | -$37.8M |
|
303
Syndax Pharmaceuticals
SNDX
$1.8B
| – | – |
-1,238,196
| Closed | -$26M |
|
304
TG Therapeutics
TGTX
$8.53B
| – | – |
-716,414
| Closed | -$21.4M |
|
305
Trade Desk
TTD
$6.31B
| – | – |
-137,471
| Closed | -$5.22M |
|
306
Veracyte
VCYT
$3.64B
| – | – |
-570,720
| Closed | -$24M |
|
307
VF Corp
VFC
$5.36B
| – | – |
-21,864
| Closed | -$399K |
|
308
Vital Farms
VITL
$448M
| – | – |
-517,988
| Closed | -$16.6M |
|
309
Verisk Analytics
VRSK
$24.9B
| – | – |
-48,002
| Closed | -$10.7M |
|
310
Wayfair
W
$14.4B
| – | – |
-4,315
| Closed | -$436K |
|
311
Wave Life Sciences
WVE
$1.02B
| – | – |
-500,000
| Closed | -$8.5M |
|
|
LIF
312
Life360
LIF
$3.61B
| – | – |
-8,319
| Closed | -$539K |
|
|
NBIS
313
Nebius Group N.V.
NBIS
$59.4B
| – | – |
-18,491
| Closed | -$1.55M |
|
|
MAZE
314
Maze Therapeutics
MAZE
$1.59B
| – | – |
-324,041
| Closed | -$13.4M |
|
Similar funds
S
CCM
O
HI
HPC
FPP
RIG
TAM
Eventide Asset Management's Q1 2026 Portfolio in Review
As of Q1 2026, Eventide Asset Management held 314 positions worth $6.05B, down 5.5% from $6.4B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Eventide Asset Management withdrew a net $238M in Q1 2026, closing 36 positions and reducing 70 holdings. Its most notable exit was Inspire Medical Systems, an estimated $40.6M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 39% of assets, down from 42% a quarter earlier, followed by Industrials and Technology.
Against the trend, Eventide Asset Management opened a new position in GeneDx Holdings worth $29.5M.
- Eventide Asset Management's largest Q1 2026 buy was GeneDx Holdings: 459,015 shares worth $29.5M.
- Eventide Asset Management added most to Generac Holdings in Q1 2026, an estimated $40.9M increase.
- Eventide Asset Management's biggest Q1 2026 reduction was Mirum Pharmaceuticals, cutting an estimated $64.4M.
- Eventide Asset Management fully exited Inspire Medical Systems in Q1 2026, selling an estimated $40.6M.
- Eventide Asset Management's ten largest holdings make up 22% of its $6.05B portfolio in Q1 2026.
- Eventide Asset Management opened 46 new positions and closed 36 in Q1 2026.
- Eventide Asset Management's portfolio value fell 5.5% quarter-over-quarter to $6.05B.
Based on Eventide Asset Management's 13F filing for Q1 2026, filed 15 May 2026.